Home
From ASH: Vertex Pharmaceuticals Presented Positive Durability Gene Editing CASGEVY for Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

From ASH: Vertex Pharmaceuticals Presented Positive Durability Gene Editing CASGEVY for Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Today’s Highlights December 9, 2024

Vertex Pharmaceuticals ASH Announcement
Today, December 8, 2024, Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT).

CASGEVY is the first and only approved CRISPR/Cas9 gene . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
,
December 9, 2024

Other Articles